# Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients

> **NCT03962816** · PHASE4 · UNKNOWN · sponsor: **Shanxi Medical University** · enrollment: 300 (estimated)

## Conditions studied

- Hepatitis B Vaccine

## Interventions

- **BIOLOGICAL:** 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
- **BIOLOGICAL:** 20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6
- **BIOLOGICAL:** 60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6

## Key facts

- **NCT ID:** NCT03962816
- **Lead sponsor:** Shanxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-26
- **Primary completion:** 2020-02
- **Final completion:** 2023-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2019-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962816, "Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03962816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*